Denali Therapeutics (DNLI) Total Liabilities (2017 - 2025)
Historic Total Liabilities for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $129.4 million.
- Denali Therapeutics' Total Liabilities fell 449.68% to $129.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.4 million, marking a year-over-year decrease of 449.68%. This contributed to the annual value of $144.5 million for FY2024, which is 1751.18% up from last year.
- According to the latest figures from Q3 2025, Denali Therapeutics' Total Liabilities is $129.4 million, which was down 449.68% from $139.2 million recorded in Q2 2025.
- Denali Therapeutics' 5-year Total Liabilities high stood at $442.6 million for Q1 2023, and its period low was $115.5 million during Q2 2024.
- For the 5-year period, Denali Therapeutics' Total Liabilities averaged around $270.8 million, with its median value being $148.7 million (2025).
- Its Total Liabilities has fluctuated over the past 5 years, first soared by 20110.22% in 2021, then tumbled by 7162.11% in 2024.
- Denali Therapeutics' Total Liabilities (Quarter) stood at $441.9 million in 2021, then dropped by 5.44% to $417.8 million in 2022, then tumbled by 70.57% to $123.0 million in 2023, then grew by 17.51% to $144.5 million in 2024, then fell by 10.43% to $129.4 million in 2025.
- Its Total Liabilities stands at $129.4 million for Q3 2025, versus $139.2 million for Q2 2025 and $148.7 million for Q1 2025.